Central banks in several major economies currently keep interest rates at restrictive levels as they work to contain inflation. That backdrop can keep market sentiment jumpy and income harder to find. Reliable dividend powerhouses with yields above 5% and well covered payouts offer a clearer source of cash flow. This article walks through three stocks from the Dividend Powerhouses screener that stand out on yield quality and consistency.
The three dividend stocks highlighted below are just a sample, and the full screen surfaced 454 more companies with similarly robust income profiles and investor stories that are not covered here. If you are serious about building a high-yield, well covered income list, head straight to the Dividend Powerhouses (3%+ Yield) screener to identify, filter and analyze the highest conviction opportunities.
Canon is a diversified Japanese equipment maker that sells printers, cameras, medical imaging systems and industrial machinery across global markets. Printing is the engine of the business at about ¥2.5t in revenue, ahead of Imaging at roughly ¥1.1t, with Medical contributing around ¥579b and Industrial about ¥347b. This gives Canon multiple income streams tied to office, healthcare and factory demand. The company is large in scale with a market cap of roughly ¥3.9t, putting it firmly in the global blue chip bracket.
Income focused investors may want Canon on their radar because it couples a high yield with earnings that Simply Wall St currently rates as high quality, supported by a 5 year earnings growth average and improving profit margins that recently sat near 7.4%. The stock trades on a P/E below both the broader tech industry and the platform’s fair value estimate, which can be helpful when you want income without paying a premium. On the other hand, the company has an unstable dividend history and a balance sheet that leans on higher risk borrowing, so investors are being paid to accept some funding and payout uncertainty. Canon’s steady product pipeline, including award winning commercial printers in 2026, adds another layer for investors who care about how a 3%+ yield is being earned, not just the size of the cheque.
Canon’s mix of high quality earnings, a below industry P/E and a multi engine business can look like income that the market has not fully priced. The real question is whether that yield properly reflects its funding and dividend risks or if the story suggested by the 4 key rewards and 1 important warning sign
Canon and the other two stocks in this list are all examples of what you can surface with the right filters in a screener. Use our flexible Screener to mix yield, valuation, balance sheet and risk metrics to suit your style, or lean on the curated themes in our Investing Ideas.
Tokio Marine Holdings is a global insurance group that offers a wide range of non life and life insurance products, from everyday auto and property cover to specialist lines like cyber, natural catastrophe and carbon credit insurance, along with various financial and risk management services. The company is large in scale with a market cap of about ¥14.7t, which places it among the bigger insurers listed in Japan.
Tokio Marine stands out in this dividend focused list because it combines a 3.2% yield with an active share buyback program and a long history in insurance solutions that now extends into areas like disaster resilience and carbon markets. Recent buybacks in 2026 and a higher proposed dividend indicate a clear capital return focus. At the same time, the Re New initiative and push into solution style products aim to support earnings quality over time. The catch is that recent profit margins have come under pressure and the stock trades on a richer P/E than many peers, so investors need to weigh the appeal of quality earnings, governance reforms and potential ROE improvement against funding risk and reliance on equity divestments that could prove less comfortable if markets turn.
Tokio Marine’s capital returns story is accelerating, with buybacks, a 3.2% yield and a richer P/E that may be signaling something investors are overlooking. Get the full context in the 3 key rewards and 1 important warning sign
Daiichi Sankyo Company is a Japan based pharmaceutical group focused on cancer and specialty treatments, selling branded drugs like Enhertu, Datroway, Vanflyta and a range of cardiovascular, diabetes and vaccine products. It currently reports essentially all of its ¥2,223,188 million revenue from its Pharmaceutical Operation segment and has a market cap of about ¥5.1t, which puts it among the larger listed pharma companies in Japan.
Income investors may want Daiichi Sankyo Company on their watchlist because it blends a roughly 3.6% dividend yield with exposure to high demand oncology drugs such as Enhertu, Datroway and Vanflyta. These drugs are supported by fresh approvals in the US, EU and China and an upgraded revenue outlook in July 2026. That story comes with real tension, as cash flow currently does not fully cover dividends, growth is heavily tied to a small group of blockbuster drugs and funding leans on higher risk borrowing. The interest lies in whether this mix of premium oncology assets, a deep antibody drug conjugate pipeline and significant upside to some fair value estimates can outweigh the dividend coverage and concentration risks that the market is still debating.
Daiichi Sankyo Company’s oncology engine looks powerful, yet the dividend and funding mix raises real questions. Get the full story in the full narrative for Daiichi Sankyo Company
Fresh stock ideas can move quickly. By the time the crowd catches on, early entry points can be gone. Use focused screeners to spot under the radar potential while it matters and consider acting promptly based on your own research and risk tolerance.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com